Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 9/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CASP9 | P55211 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.52 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484211 | 0.82 | CYP1A2 (0.56) | CYP1A2SMN1; SMN2GSK3BCCNB2CDK1 | |
| SCHEMBL659375 | 0.77 | AHR (0.48) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL29550002 | 0.77 | AHR (0.48) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL2223651 | 0.75 | CA12 (0.50) | TDP2CYP1A2SMN1; SMN2CDK5GAA | |
| SCHEMBL585349 | 0.73 | TDP1 (0.42) | TDP2CYP1A2SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL30975576 | 0.72 | TDP2 (0.41) | TDP2CYP1A2SMN1; SMN2CDK5ALDH1A1 | |
| SCHEMBL299004 | 0.72 | PARP1 (0.53) | CYP1A2 | |
| SCHEMBL29572479 | 0.70 | CYP1A2 (0.50) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL4670599 | 0.70 | TDP2 (0.39) | TDP2CYP1A2SMN1; SMN2CDK5CDK5R1 | |
| SCHEMBL5394514 | 0.70 | TDP2 (0.52) | TDP2CASP3CASP7CASP9CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504724-A1 | SPLEEN TYROSINE KINASE INHIBITORS | Uniquest Pty Limited (AU) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023193054-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023102800-A1 | SYNTHESIS OF 5, 7-DICHLORO-1, 6-NAPHTHYRIDINE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-113651820-A | Urea compounds for dual IDO and TDO inhibitors | 正大天晴药业集团股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-2563789-B1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LTD (GB) | 2015-05-20 | — | — | EP | disclosed |
| EP-2563789-B1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LTD (GB) | 2015-05-20 | — | — | EP | disclosed |
| US-8633319-B2 | 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors | GLAXO GROUP LIMITED (GB) | 2014-01-21 | — | — | US | disclosed |
| US-8633319-B2 | 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors | GLAXO GROUP LIMITED (GB) | 2014-01-21 | — | — | US | disclosed |
| US-8633319-B2 | 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors | GLAXO GROUP LIMITED (GB) | 2014-01-21 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| EP-2086975-B1 | 7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011134971-A1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-7723355-B2 | 7,8-dihydro-1,6-naphthyridin-5(6H)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2086975-A2 | 7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090149492-A1 | 7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-11 | — | — | US | disclosed |
| WO-2008064107-A2 | 7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| US-7192967-B1 | Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents | ASTELLAS PHARMA GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | SYK, BTK, LYN | TDP2 3171/4885CASP3 1699/4885CASP7 757/4885 |
| US-20090149492-A1 | 7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | DPP4, DPP7, DPP8 | TDP2 1440/4885CASP3 445/4885CASP7 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.